of the contents; and, Section 502 (f) (1), the labeling of the repackaged drugs failed to bear adequate directions for use.

Further misbranding, Section 502 (d), the repackaged *pentobarbital sodium capsules* contained a chemical derivative of barbituric acid, which derivative has been found to be, and by regulations designated as, habit forming; and the repackaged capsules failed to bear a label containing the name, and quantity or proportion of such derivative and in juxtaposition therewith the statement "Warning—May be habit forming."

Further misbranding, Section 502 (e) (1), the repackaged *amphetamine sulfate tablets* failed to bear a label containing the common or usual name of the drug; and, Section 502 (f) (2), the labeling of the repackaged *amphetamine sulfate tablets* failed to bear adequate warnings against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and methods and duration of administration, in such manner and form, as are necessary for the protection of users.

DISPOSITION: April 6, 1953. Pleas of guilty having been entered by the defendants, the court placed each defendant on probation for two years and fined Defendant Smith $500.

3970. Misbranding of dextro-amphetamine sulfate tablets and Seconal Sodium capsules. U. S. v. Lonnie Jackson (Jackson's Drug Store). Plea of guilty. Fine, $500. (F. D. C. No. 34358. Sample Nos. 31034–L, 34327–L, 34388–L.)

INFORMATION FILED: February 24, 1953, Western District of Missouri, against Lonnie Jackson, trading as Jackson's Drug Store, Springfield, Mo.

ALLEGED VIOLATION: On or about March 21 and 26, 1952, while a number of *dextro-amphetamine sulfate tablets* and *Seconal Sodium capsules* were being held for sale at Jackson's Drug Store, after shipment in interstate commerce, the defendant caused various quantities of the drugs to be repacked and dispensed without a physician's prescription, which acts resulted in the repackaged drugs being misbranded.

NATURE OF CHARGE: Misbranding, Section 502 (b) (2), the repackaged drugs failed to bear a label containing an accurate statement of the quantity of the contents; and, Section 502 (f) (1), the labeling of the repackaged drugs failed to bear adequate directions for use.

Further misbranding, Section 502 (b) (1), the repackaged *Seconal Sodium capsules* failed to bear a label containing the name and place of business of the manufacturer, packer, or distributor.

Further misbranding, Section 502 (d), the repackaged *Seconal Sodium capsules* contained a chemical derivative of barbituric acid, which derivative has been found to be, and by regulations designated as, habit forming; and the repackaged capsules failed to bear a label containing the name, and quantity or proportion of such derivative and in juxtaposition therewith the statement "Warning—May be habit forming."

Further misbranding, Section 502 (e) (2), the repackaged *dextro-amphetamine sulfate* tablets failed to bear a label containing the common or usual name of each active ingredient of the drug.

DISPOSITION: April 7, 1953. The defendant having entered a plea of guilty, the court fined him $500.